Table 1.
Characteristics and summary from studies included.
| Study | Study Design | Year of Publication | Population | Number of Pregnancies Included in This Study | Indication for Treatment | Treatment; Doses | Outcome | Notes |
|---|---|---|---|---|---|---|---|---|
| 1 | Case report |
2009 | 1 | 1 | AOSD | Anakinra; 100 mg/day |
Healthy term baby | |
| 2 | Case report |
2011 | 2 | 2 | AOSD | Anakinra; 100 mg/day |
Two healthy babies, one PTB 36 weeks | |
| 3 | Retrospective cohort study | 2013 | 51 | 1 | SOJIA | Anakinra; NA | Term baby | Big cohort of SOJIA patients but only one pregnant |
| 4 | Prospective cohort study |
2014 | 9 | 9 | FCAS (6) NOMID (1) MWS/NOMID (1) |
Anakinra; mostly 100 mg/day but also 239–300 mg/day | All term babies, three with FCAS, one with MWS and one twin pregnancy resulted in one death at 30 weeks | |
| 5 | Prospective cohort study |
2015 | 4 | 0 | FMF | Anakinra; 100 mg/day |
All healthy babies, one PTB 36 weeks | Data in another study already included |
| 6 | Prospective cohort study |
2015 | 6 | 3 | FMF | Anakinra; 100 mg/day or NA |
All healthy babies, one PTB 36 weeks | Data in another study already included |
| 7 | Prospective cohort study |
2015 | 79 | 1 | Chronic inflammatory rheumatic disease |
Anakinra; NA | Voluntary pregnancy termination | Big cohort of biological drug during pregnancy, only one took anakinra |
| 8 | Case report |
2017 | 1 | 1 | FMF | Anakinra; 100 mg/day |
Healthy term baby | |
| 9 | Prospective cohort study |
2018 | 5 | 5 | AOSD (3) SOJIA (2) |
Anakinra; 100 mg/day |
All healthy term babies but one with right hydrocele, heart murmur and resolved low birthweight |
|
| 10 | Retrospective cohort study | 2018 | 4 | 4 | FMF | Anakinra; 100 mg/day–2 days |
All healthy babies but one PTB at 33 weeks with hypotrophic, respiratory distress syndrome, hyperbilirubinemia and poor drinking |
|
| 11 | Prospective cohort study |
2019 | 13 | 12 | FMF | Anakinra; 100 mg/day or NA |
One miscarriage, two PTB, one stillbirth but overall healthy babies | Two pregnancies still ongoing, no obstetrical information and two pregnancies with data in another study already included |
| 12 | Case report |
2019 | 1 | 1 | FMF | Anakinra; 100 mg/day |
Term healthy baby | Cohort of four patients with FMF, only one pregnant |
| 13 | Prospective cohort study |
2019 | 54 | 1 | FMF | Anakinra; 100 mg/day |
Obstetrical and neonatal information NA |
Cohort of patient with FMF, only one pregnant |
| 14 | Case report |
2019 | 1 | 1 | HLH | Anakinra; 200 mg/twice daily |
Healthy but had anaemia and marrow suppression | |
| 15 | Retrospective cohort study | 2020 | 16 | 3 | AOSD | Anakinra; NA | All healthy babies but one had PTB at 28 weeks | Cohort of child exposed to DMARDs, only 3 exposed to anakinra during pregnancy |
| 16 | Case report |
2020 | 1 | 1 | HLH | Anakinra; NA | PTB at 31 weeks and IUGR but overall healthy | |
| 17 | Case report |
2017 | 1 | 1 | MWS | Canakinumab; 150 mg/ 4–8 weeks |
Healthy term baby | |
| 18 | Case report |
2018 | 1 | 1 | SOJIA | Canakinumab; NA | Healthy term baby | |
| 19 | Retrospective cohort study | 2020 | 23 | 1 | FMF | Canakinumab; 150 mg/ 6–8 weeks |
One healthy term pregnancy and one without information | Cohort of patient with FMF, only 2 pregnant |
| 20 | Retrospective cohort study | 2013 | 7 | 7 | AOSD (1) CAPS (3) TRAPS (1) FMF (1) Idiopathic pericarditis (1) |
Anakinra; NA (6), Canakinumab; NA (1) |
All healthy babies, one PTB 36 weeks and one with unilateral reduced hearing at 6 weeks | Two pregnancies still ongoing, no obstetrical information |
| 21 | Case report |
2015 | 1 | 1 | MWS | Canakinumab; NA and Anakinra; NA | Healthy but with CAPS | |
| 22 | Retrospective cohort study | 2017 | 43 | 31 | AOSD (4) CAPS (16) Cogan syndrome (2) FMF (5) Idiopathic pericarditis (1) TRAPS (2) Un-SAID (1) |
Anakinra; mostly 100 mg/day but also 50–300 mg/day Canakinumab; 150 mg/ 4–8 weeks |
Two miscarriage (same women), two PTB, all healthy babies but one with left renal agenesis and ectopic neurohypophysis with hormone deficiency |
43 pregnancies exposed to IL-1 inhibitor but 11 were male exposure |
HLH: hemophagocytic lymphohistiocytosis, FMF: familial mediterranean fever, AOSD: adult-onset Still’s disease, FCAS: familial cold autoinflammatory Syndrome, NOMID: neonatal-onset multisystem inflammatory disease, MWS: Muckle-Wells syndrome, sJIA: systemic juvenile idiopathic arthritis, CAPS: cryopyrin-associated autoinflammatory syndromes, NA: not available.